#United States #Newtown #Edelson Lechtzin LLP #Soleno Therapeutics #SLNO

Investigation of Soleno Therapeutics, Inc.

Edelson Lechtzin LLP, a prominent class-action law firm, has launched an investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO) amid allegations of possible violations of federal securities laws. Investors who have experienced significant losses or possess relevant information regarding these allegations are encouraged to contact the firm to assist in the ongoing inquiry.

Background of Soleno Therapeutics

Founded with the aim of developing innovative treatments for rare diseases, Soleno Therapeutics has garnered attention in the biopharmaceutical industry, particularly after the U.S. Food and Drug Administration (FDA) approved their drug, VYKAT XR, on March 26, 2025. This medication is designed for treating hyperphagia in patients with Prader-Willi syndrome aged four years and older. The excitement around this announcement, however, quickly diminished when the company reported concerning insights shortly thereafter.

The Alleged Wrongdoings

On November 4, 2025, Soleno disclosed a troubling 8% discontinuation rate for VYKAT XR, as patients experienced adverse side effects. Furthermore, the company mentioned that a negative report from short-sellers published in mid-August played a role in slowing down the drug's rollout to market. Following this revelation, Soleno's stock price plunged by over 26%, leading to a stark realization of the risks involved in investing in the company. These drastic fluctuations have raised significant questions about the accuracy and completeness of Soleno's business disclosures to the investing public.

Steps for Affected Investors

Edelson Lechtzin encourages any investor who feels misled or who has suffered financial losses as a result of Soleno's actions to step forward. Information can be submitted online, or investors may directly reach out to attorney Eric Lechtzin at the firm via phone or email. The firm is dedicated to pursuing justice for those affected by potential infringements on their investment rights and intends to investigate thoroughly.

Why This Matters

The investigation into Soleno Therapeutics highlights a broader issue that affects not only investors but also the ethos of transparency in the pharmaceutical industry. As companies innovate and bring new drugs to market, they hold the responsibility to provide truthful and comprehensive information to their investors. Misleading data can significantly impact investment decisions and market movements, underlining the necessity of accountability.

Edelson Lechtzin LLP, headquartered in Newtown, PA, is recognized for its aggressive pursuit of justice in cases involving securities fraud and investment malpractice. With a skilled team experienced in class-action litigation, the firm is well-equipped to handle complex cases in corporate law that advocate for investors' rights.

Conclusion

As the situation develops, investors are advised to stay informed about the unfolding investigation surrounding Soleno Therapeutics. By cooperating with investigations and ensuring that corporate conduct remains in check, stakeholders can contribute to maintaining integrity within the market. Any parties with pertinent information are strongly encouraged to contact Edelson Lechtzin LLP, as their insights could prove invaluable as the firm seeks to ensure fair treatment for all affected investors.